fondaparinux has been researched along with Genital-Neoplasms--Female* in 1 studies
1 other study(ies) available for fondaparinux and Genital-Neoplasms--Female
Article | Year |
---|---|
Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience.
To analyze clinical characteristics of venous thromboembolisms (VTE) in gynecological malignancies, and to find a cost-effective prophylaxis procedure for post-operative VTE.. We analyzed clinical characteristics of 751 patients who underwent definitive surgery for gynecologic malignancies, and cost-effectiveness of VTE prophylaxis.. VTE was diagnosed preoperatively in 4.5% of ovarian cancer cases, more frequently than any other type (p<0.005). Older age and greater length of operation were independent risk factors for postoperative VTE. To prevent eight VTEs in 738 malignant cases, which occurred during day 2 to 10, $617,783, $726,185, or $994,222 were necessary for continuous VTE prophylaxis, using either unfractionated heparin (UFH), low-molecular weight heparin or fondaparinux, respectively.. A strategy which might be cost-effective for post-surgical management of gynecological malignances is use of UFH three times combined with graduated compression stockings and intermittent pneumatic compression, thorough SpO2 monitoring, and perioperative measurements of the circumference of both sides of thighs and calves. Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Female; Fondaparinux; Genital Neoplasms, Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Japan; Middle Aged; Perioperative Period; Polysaccharides; Venous Thromboembolism | 2014 |